Health Trials

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

ConditionsOvarian CancerFallopian Tube CancersPrimary Peritoneal Cancer
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorN.N. Alexandrov National Cancer Centre

About this trial

This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.

Eligibility criteria

Qualifiers

Age ≥18-≤75 years.

Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Possibility of performing diagnostic laparoscopy or cytoreductive surgery.

Disqualifiers

Presence of another active malignant invasive neoplasm.

Pregnancy or lactation period.

Disease progression during treatment.

Trial design

Treatments tested in this trial

  • PARP inhibitor + Bevacizumab
  • PARP inhibitor

Treatment groups

120 Participants
are divided into 2 treatment groups

Sponsors and collaborators

N.N. Alexandrov National Cancer Centre

Lead sponsor

Source ClinicalTrials.gov